Psoriasis

Patients with psoriasis seem to suffer more in the wintertime when flare-ups are much more common.

More drugs and treatment options continue to be explored, and in 2022, there were some exciting advancements in these areas for dermatologists treating psoriasis.

Click here to answer this week's poll.

A variety of topicals and biologics are now available to treat children affected by this challenging condition.

Patient enrollment is now open for the study conducted by late-stage biopharmaceutical company, Soligenix.

Arcutis Biotherapeutics' indication expansion is based on data from MUSE studies.

A biologic from Germany offers a new treatment option for a number of dermatologic conditions.

Aaron S. Farberg, MD, and Jeffrey Crowley, MD, share take-home messages on the impact of the generalized pustular psoriasis study.

Aaron S. Farberg, MD, and Jeffrey Crowley, MD, discuss study limitations regarding health records in generalized pustular psoriasis and how the number of flares could be underestimated.

Aaron S. Farberg, MD, and Jeffrey Crowley, MD, discuss the importance of investigating the data on generalized pustular psoriasis, comorbidities of the disease, and commonly used treatments.

Experts in dermatology review data on various treatment interventions before, during, and after generalized pustular psoriasis flare episodes.

Recent review explores the difficulties of treating pediatric psoriasis.

New research examined brain structure and connectivity in patients with psoriasis.

Arcutis Biotherapeutics announced new positive data involving itch and itch-related sleep loss in adults with plaque psoriasis.

Drs Mark G. Lebwohl and Alice B. Gottlieb discuss future expectations in the treatment of plaque psoriasis.

Aaron S. Farberg, MD, and Jeffrey Crowley, MD, examine the results of a study of generalized pustular psoriasis, discussing flares and common signs and symptoms.

Aaron S. Farberg, MD, and Jeffrey Crowley, MD, review the demographics of people with generalized pustular psoriasis including age, race, and comorbidities.

Mark G. Lebwohl, MD, and Alice B. Gottlieb, MD, PhD, discuss gaps in care for the treatment of plaque psoriasis.

Expert dermatologists discuss the methods of a study of US health records of patients with generalized pustular psoriasis.

Aaron S. Farberg, MD, and Jeffrey Crowley, MD, provide an overview of generalized pustular psoriasis, identifying flares, the burden on patients, and available treatment options.

Shanna Miranti, MPAS, PA-C, shares highlights from her shared session at the 2022 SDPA Conference.

In the past, there were many efforts to develop topical MTX, but the major obstacle was its physicochemical properties.

Psoriasis has long been linked to cardiovascular disease, including coronary artery disease, myocardial infarction, and heart failure.

Dr Mark Lebwohl provides insight into the educational needs of both patients and providers surround the utilization of spesolimab and its importance in the management of patients with generalized pustular psoriasis.

Mark G. Lebwohl, MD, comments on the clinical implications of the recent approval of spesolimab for the treatment of generalized pustular psoriasis.